Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZS-1002
- Development stage
- Preclinical
- Lead developer
- Genuine Biotech
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ZS-1002 is a small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) being developed by Bio Genuine (GenuineBiotech) for the treatment of solid and malignant tumors. ENPP1 is a phosphodiesterase that is frequently overexpressed in tumors characterized by chromosomal instability; it facilitates immune evasion by degrading cyclic GMP-AMP (cGAMP), the endogenous ligand that activates the stimulator of interferon genes (STING) pathway. By inhibiting ENPP1, ZS-1002 prevents the degradation of cGAMP, thereby promoting the activation of the cGAS-STING innate immune pathway and enhancing anti-tumor immune responses within the tumor microenvironment.
02
Targets
ENPP1
Beyond the preview
Go deeper on ZS-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZS-1002.